Literature DB >> 19526389

The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia.

William R Prather1, Amir Toren, Moran Meiron, Racheli Ofir, Carsten Tschope, Edwin M Horwitz.   

Abstract

BACKGROUND AIMS: Mesenchymal stromal cells (MSC) are spindle-shaped plastic-adherent cells isolated from bone marrow (BM), adipose tissue and other organs, including the placenta. Autologous BM-derived MSC have been studied in animals with experimentally induced critical limb ischemia (CLI) as a model of end-stage peripheral vascular disease. While demonstrating therapeutic benefit, the use of these cells is limited by the need to surgically extract BM and the fear of thrombosis secondary to the use of granulocyte-colony-stimulating factor (G-CSF) to mobilize the cells.
METHODS: We studied the use of placental-derived adherent stromal cells (ASC) in a standard limb ischemia model of male Balb/c mice. These placental-derived cells, termed PLX-PAD, share the adherence and marker expression of BM-derived MSC but lack their differentiation potential. PLX-PAD are isolated from human placenta following a Caesarean section and cultured in a bioreactor, termed the PluriX System. The PluriX System provides a three-dimensional (3-D) microenvironment that enables the large-scale growth of these cells. PLX-PAD are stable adhesive cells that can be expanded in vitro without the loss of phenotype and without showing signs of karyotypic changes.
RESULTS: The intramuscular (i.m.) administration of PLX-PAD in our model significantly improved blood flow (BF) (P=0.0008), increased capillary density (P=0.021), reduced oxidative stress (P=0.034) and reduced endothelial damage (P=0.004), while increasing limb function versus the administration of a phosphate-buffered saline (PBS) control vehicle in the affected limb.
CONCLUSIONS: Allogeneic placental-derived ASC may provide an off-the-shelf supply of therapeutic cells that would need no histocompatible tissue matching and be potentially less expensive and considerably more convenient than BM or adipose-derived MSC.

Entities:  

Mesh:

Year:  2009        PMID: 19526389     DOI: 10.1080/14653240902849762

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  50 in total

1.  Chorion Mesenchymal Stem Cells Show Superior Differentiation, Immunosuppressive, and Angiogenic Potentials in Comparison With Haploidentical Maternal Placental Cells.

Authors:  Paz L González; Catalina Carvajal; Jimena Cuenca; Francisca Alcayaga-Miranda; Fernando E Figueroa; Jorge Bartolucci; Lorena Salazar-Aravena; Maroun Khoury
Journal:  Stem Cells Transl Med       Date:  2015-08-13       Impact factor: 6.940

Review 2.  Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis.

Authors:  Suja Ann Mathew; Charuta Naik; Paul A Cahill; Ramesh R Bhonde
Journal:  Cell Mol Life Sci       Date:  2019-08-29       Impact factor: 9.261

Review 3.  Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball.

Authors:  Carsten Tschöpe; Sophie Van Linthout; Behrouz Kherad
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

Review 4.  Cell based therapies for ischemic stroke: from basic science to bedside.

Authors:  Xinfeng Liu; Ruidong Ye; Tao Yan; Shan Ping Yu; Ling Wei; Gelin Xu; Xinying Fan; Yongjun Jiang; R Anne Stetler; George Liu; Jieli Chen
Journal:  Prog Neurobiol       Date:  2013-12-12       Impact factor: 11.685

Review 5.  Eminent Sources of Adult Mesenchymal Stem Cells and Their Therapeutic Imminence.

Authors:  Dannie Macrin; Joel P Joseph; Aruthra Arumugam Pillai; Arikketh Devi
Journal:  Stem Cell Rev Rep       Date:  2017-12       Impact factor: 5.739

6.  Treatment of hind limb ischemia using angiogenic peptide nanofibers.

Authors:  Vivek A Kumar; Qi Liu; Navindee C Wickremasinghe; Siyu Shi; Toya T Cornwright; Yuxiao Deng; Alon Azares; Amanda N Moore; Amanda M Acevedo-Jake; Noel R Agudo; Su Pan; Darren G Woodside; Peter Vanderslice; James T Willerson; Richard A Dixon; Jeffrey D Hartgerink
Journal:  Biomaterials       Date:  2016-04-26       Impact factor: 12.479

7.  Cell Therapy and Critical Limb Ischemia: Evidence and Window of Opportunity in Obesity.

Authors:  Sally L Elshaer; Renee E Lorys; A B El-Remessy
Journal:  Obes Control Ther       Date:  2016-09-15

Review 8.  Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies.

Authors:  Raphael Gorodetsky; Wilhelm K Aicher
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

9.  Ontological differences in first compared to third trimester human fetal placental chorionic stem cells.

Authors:  Gemma N Jones; Dafni Moschidou; Tamara-Isabel Puga-Iglesias; Katarzyna Kuleszewicz; Maximilien Vanleene; Sandra J Shefelbine; George Bou-Gharios; Nicholas M Fisk; Anna L David; Paolo De Coppi; Pascale V Guillot
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

Review 10.  Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia.

Authors:  Aaron Liew; Timothy O'Brien
Journal:  Stem Cell Res Ther       Date:  2012-07-30       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.